SOPHiA GENETICS has demonstrated a proof of concept for real time global variant surveillance of spike protein mutations through the SOPHiA GENETICS' secured peer-network and compared findings to the GISAID timeline. Paragon Genomics SARS-CoV-2 panels powered by the SOPHiA DDM™ Platform enables labs to detect current and emerging variants with high accuracy and confidence. In this case study, SOPHiA GENETICS' extensive experience in sequencing analytics generates high-quality viral genome data for better research and surveillance of SARS-CoV-2. 

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.